Injection containing sodium hyaluronate as well as preparation method and application of injection
By cross-linking the complex of sodium hyaluronate with amino acids, animal collagen and cell extracts, a stable structure is formed, which solves the degradation of sodium hyaluronate injection and the skin softness problems, and achieves stability and elastic effects. promote.
Patent Information
- Application Number
- CN202411457341.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-12-03
AI Technical Summary
Existing sodium hyaluronate injections are prone to degradation during storage, unstable effects, and may lead to allergic reactions, and the skin lacks natural softness after injection of high molecular weight products.
The combination of crosslinked sodium hyaluronate with specific amino acids, animal collagen and cell extracts is prepared by crosslinking agents and enzymatic decomposition to form a stable three-dimensional network structure, which delays degradation and improves skin elasticity.
It significantly delays the degradation rate of sodium hyaluronate, improves the stability and skin elasticity of the injection, reduces the risk of allergic reactions, and is suitable for the medical and cosmetics fields.
Smart Images

Figure BDA0005090852650000131
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to an injection containing sodium hyaluronate and a preparation method and application thereof. Background Art
[0002] Sodium Hyaluronate is a substance widely used in skin care and medical cosmetology. Sodium Hyaluronate is a transparent, odorless high-molecular polysaccharide substance with excellent water-retaining properties. It can form a protective film in the skin to maintain the moisture balance of the skin, thereby improving the appearance and texture of the skin. Sodium Hyaluronate injection can be directly injected into the dermis of the skin to help hydrate the deep layers of the skin and improve dry, dehydrated skin conditions. Sodium Hyaluronate injection is considered a relatively safe treatment method due to its natural ingredients and good biocompatibility.
[0003] Injections containing sodium hyaluronate are a very common filler, mainly used for skin hydration, facial filling, wrinkle improvement, etc. However, in actual applications, this type of injection may face some technical and operational problems: (1) Sodium hyaluronate injection may degrade during storage, resulting in a decrease in its effectiveness; (2) The molecular weight of sodium hyaluronate has a great influence on its effect, and products with different molecular weights have different properties; (3) The effect of sodium hyaluronate injection is usually not permanent and requires regular re-injection; (4) Some patients may have allergic reactions to sodium hyaluronate or other ingredients in the injection.
[0004] In order to prolong the retention time of sodium hyaluronate on the face, high molecular weight sodium hyaluronate is currently mainly selected. High molecular weight sodium hyaluronate is more difficult to be decomposed by enzymes and usually stays longer in the body. However, too much high molecular weight sodium hyaluronate may cause the filler to feel harder after injection and lack natural softness.
[0005] Therefore, there is an urgent need for an injection containing sodium hyaluronate and a preparation method and application thereof. Summary of the invention
[0006] The purpose of the present invention is to provide an injection containing sodium hyaluronate and a preparation method and application thereof.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] An injection containing sodium hyaluronate, comprising the following components in parts by weight:
[0009] 1.4-1.8 parts of cross-linked sodium hyaluronate, 0.4-0.9 parts of carnosine, 0.4-0.6 parts of amino acids, 0.2-0.6 parts of vitamin B3, 0.8-1.2 parts of sodium chloride, 0.002-0.008 parts of sodium dihydrogen phosphate, 0.01-0.02 parts of sodium dihydrogen phosphate, 0.1-0.3 parts of animal collagen and 95-100 parts of water for injection;
[0010] The preparation method of the cross-linked sodium hyaluronate comprises the following steps:
[0011] (1) mixing medium molecular sodium hyaluronate, large molecular sodium hyaluronate and ultra-large molecular sodium hyaluronate to obtain mixed sodium hyaluronate;
[0012] (2) adding a 0.5-0.9 mol / L sodium hydroxide aqueous solution to 100 parts by weight of the mixed sodium hyaluronate to adjust the pH to 10-11, and then adding 1-3 parts by weight of a cross-linking agent, stirring and reacting at 20-30° C. for 4-6 hours;
[0013] (3) continuing to add 320-350 parts by weight of ethanol to precipitate, and then adding 2-5% by weight of a hydrogen chloride aqueous solution to adjust the pH value to neutral to obtain a precipitate; washing the precipitate with ethanol 3-5 times, and filtering to obtain a wet powder;
[0014] (4) The wet powder is vacuum dried at 30-40° C. to obtain cross-linked sodium hyaluronate.
[0015] Furthermore, the weight ratio of medium molecular sodium hyaluronate, large molecular sodium hyaluronate and super large molecular sodium hyaluronate is (1.2-1.5):1:(0.4-0.7).
[0016] Furthermore, the molecular weight of the medium-molecular sodium hyaluronate is 400K-500KDa; the molecular weight of the large-molecular sodium hyaluronate is 1300K-1400KDa; and the molecular weight of the ultra-large-molecular sodium hyaluronate is 1700K-1800KDa.
[0017] Furthermore, the cross-linking agent is a mixture of 1,4-butanediol diglycidyl ether, genipin, and ethylene glycol diglycidyl ether in a weight ratio of 1: (1.2-1.4): (0.5-0.8).
[0018] The present invention attempts to use a cross-linking agent to cross-link sodium hyaluronate to slow down the degradation rate of sodium hyaluronate, but the actual improvement effect cannot meet the increasingly high requirements of consumers. The present invention cross-links the compounded sodium hyaluronate after compounding three cross-linking agents, which can significantly slow down the degradation rate of sodium hyaluronate. The three cross-linking agents of the present invention have a synergistic effect. By cross-linking with three sodium hyaluronates of different molecular weights, a more stable three-dimensional network structure can be formed, thereby slowing down degradation.
[0019] Genipin, CAS: 6902-77-8.
[0020] Furthermore, the amino acids include the following components in parts by weight: 1-3 parts of arginine, 5-8 parts of serine, 3-6 parts of leucine, 2-4 parts of alanine and 5-8 parts of cysteine.
[0021] The amino acids prepared by compounding in the present invention have a more significant inhibitory effect on hyaluronidase.
[0022] Furthermore, the method for preparing animal collagen comprises the following steps:
[0023] (1) crushing cod bones and passing through a 100-200 mesh sieve to obtain cod bone powder;
[0024] (2) mixing cod bone powder and a sodium chloride aqueous solution with a weight ratio of 1: (6-10) and soaking for 12-15 hours, filtering and retaining the precipitate, washing with deionized water for 3-5 times, drying, adding ethyl acetate 5-7 times the weight of the cod bone powder and soaking again for 8-10 hours, filtering, drying, and finally crushing to 50-100 mesh to obtain pretreated cod bone powder;
[0025] (3) Pretreated cod bone powder and water at 35-37° C. in a weight ratio of 1:(35-40) are mixed to obtain a mixed liquid, a composite enzyme is added, and after enzymatic hydrolysis for 5-7 hours, the mixed liquid is filtered, and the filtrate is added with a 2.4-2.6 mol / L sodium chloride aqueous solution for salting out for 1-2 hours, centrifuged, and the supernatant is collected and dialyzed to retain substances with a molecular weight between 30,000 Da and 50,000 Da, which are freeze-dried to obtain animal collagen.
[0026] Further, the complex enzyme includes pepsin, papain and trypsin.
[0027] Furthermore, the amount of pepsin used in the mixed liquid is 60-70 U / mL; the amount of papain used in the mixed liquid is 110-120 U / mL; and the amount of trypsin used in the mixed liquid is 80-90 U / mL.
[0028] The present invention attempts to improve the elasticity of the skin after injection by adding animal collagen, but the effect is not ideal. The animal collagen prepared by enzymolysis using three specific enzymes can improve the elasticity of the skin after injection. The components in the animal collagen of the present invention can act on the skin better, and the cross-linked sodium hyaluronate and collagen have a synergistic effect. The cross-linked sodium hyaluronate and collagen act on the skin together, the former provides moisture support, and the latter provides structural support. The two together enhance the elasticity and firmness of the skin. The moisturizing effect of cross-linked sodium hyaluronate can create a good repair environment for the skin, and collagen is directly involved in the repair process of the skin. The two jointly promote the regeneration of the skin, and the two improve the elasticity of the skin through synergy.
[0029] Furthermore, according to functional requirements, the injection may also include 0.15-0.24 parts of cell extracts, wherein the cell extracts include extracts of amniotic membrane, umbilical cord and / or placental cells.
[0030] Furthermore, the method for preparing the cell extract comprises the following steps:
[0031] (1) Wash and drain the amniotic membrane, umbilical cord and placenta of a healthy full-term pregnant woman who is free of hepatitis B, hepatitis C, HIV and syphilis virus;
[0032] (2) Weighing amniotic membrane, umbilical cord and placenta in a weight ratio of 1: (1.2-1.4): (0.5-0.7) to obtain a mixed raw material, mixing the mixed raw material in a weight ratio of (4.5-5): 1 with 0.8-1.0% by weight of physiological saline, and mashing to obtain a placenta tissue slurry;
[0033] (3) mixing the placental tissue slurry in a weight ratio of 1:(4-4.5) with 0.8%-1% physiological saline by weight, and dialyzing the mixture; dialyzing the mixture three times, each time for 30-35 hours, to obtain a dialysate;
[0034] (4) Clarify the dialysate to obtain a supernatant, first filter it through a filter element with a pore size of 0.45 μm-0.75 μm, and then ultrafilter it with a membrane with a molecular weight of 6000-8000 Daltons; after ultrafiltration, inactivate the virus at 60°C±0.5°C for 10 hours to obtain a cell extract.
[0035] The invention provides a method for preparing an injection containing sodium hyaluronate, comprising mixing components in a formula amount, stirring evenly, and starting a vacuum bubble removal process to prepare the injection.
[0036] The present invention provides an application of an injection containing sodium hyaluronate. The application includes application in the preparation of medicines, or application in the preparation of pharmaceutical preparations for skin, such as cosmetic preparations, or application in the preparation of cosmetics, such as water light injections, etc.
[0037] Compared with the prior art, the advantages and beneficial effects of the present invention are:
[0038] 1. The sodium hyaluronate prepared by the present invention is safe and non-irritating, has good stability, slow degradation time, and good effect on improving skin elasticity. The injection of the present invention can be used in the medical field and can be applied to products such as hyaluronic acid injections and cosmetics.
[0039] 2. The present invention compounds three cross-linking agents and then cross-links the compounded sodium hyaluronate, which can significantly slow down the degradation rate of the sodium hyaluronate.
[0040] 3. The animal collagen prepared by the present invention is hydrolyzed by using three specific enzymes, and the cross-linked sodium hyaluronate and collagen have a synergistic effect, which can improve the elasticity of the skin after injection. DETAILED DESCRIPTION
[0041] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0042] Example 1
[0043] This embodiment provides an injection containing sodium hyaluronate, comprising the following components in parts by weight: 1.6 parts of cross-linked sodium hyaluronate, 0.7 parts of carnosine, 0.5 parts of amino acids, 0.4 parts of vitamin B3, 0.9 parts of sodium chloride, 0.007 parts of sodium dihydrogen phosphate, 0.015 parts of sodium dihydrogen phosphate, 0.2 parts of animal collagen and 97.2 parts of water for injection;
[0044] The amino acids include the following components in parts by weight: 2 parts of arginine, 6 parts of serine, 4 parts of leucine, 3 parts of alanine and 7 parts of cysteine.
[0045] The preparation method of the cross-linked sodium hyaluronate comprises the following steps:
[0046] (1) Mixing medium-molecular sodium hyaluronate, macromolecular sodium hyaluronate and ultra-large-molecular sodium hyaluronate to obtain mixed sodium hyaluronate; the weight ratio of medium-molecular sodium hyaluronate, macromolecular sodium hyaluronate and ultra-large-molecular sodium hyaluronate is 1.3:1:0.6. The molecular weight of the medium-molecular sodium hyaluronate is about 450KDa; the molecular weight of the macromolecular sodium hyaluronate is about 1320KDa; and the molecular weight of the ultra-large-molecular sodium hyaluronate is about 1750KDa;
[0047] (2) adding a 0.6 mol / L sodium hydroxide aqueous solution to 100 parts by weight of the mixed sodium hyaluronate to adjust the pH to 10.5, and then adding 2 parts by weight of a cross-linking agent, stirring and reacting at 25° C. for 5 hours; the cross-linking agent is a mixture of 1,4-butanediol diglycidyl ether, genipin, and ethylene glycol diglycidyl ether in a weight ratio of 1:1.3:0.7;
[0048] (3) adding 340 parts by weight of ethanol to precipitate, and then adding 4% by weight of a hydrogen chloride aqueous solution to adjust the pH value to neutral to obtain a precipitate; washing the precipitate with ethanol for 4 times, and filtering to obtain a wet powder;
[0049] (4) The wet powder is vacuum dried at 36° C. to obtain cross-linked sodium hyaluronate.
[0050] The preparation method of the animal collagen comprises the following steps:
[0051] (1) crushing cod bones and passing through a 100-mesh sieve to obtain cod bone powder;
[0052] (2) mixing cod bone powder and an aqueous solution of sodium chloride with a weight ratio of 1:8, soaking for 14 hours, filtering and retaining the precipitate, washing with deionized water for 4 times, drying, adding ethyl acetate 6 times the weight of the cod bone powder and soaking again for 9 hours, filtering, drying, and then crushing to 50-100 mesh to obtain a pretreated cod bone powder;
[0053] (3) Pretreated cod bone powder and water at 36° C. in a weight ratio of 1:38 are mixed to obtain a mixed liquid, and a composite enzyme is added, wherein the composite enzyme includes pepsin, papain and trypsin. The amount of pepsin used in the mixed liquid is 65 U / mL; the amount of papain used in the mixed liquid is 105 U / mL; the amount of trypsin used in the mixed liquid is 85 U / mL; after enzymatic hydrolysis for 6 hours, the mixture is filtered, and the filtrate is added with 2.5 mol / L sodium chloride aqueous solution for salting out for 1.6 hours, centrifuged, and the supernatant is collected. The supernatant is dialyzed to retain substances with a molecular weight between 30,000 Da and 50,000 Da, and freeze-dried to obtain animal collagen.
[0054] The preparation method of the injection containing sodium hyaluronate is as follows: mixing the components in the formula, stirring evenly, and starting a vacuum bubble removal process to obtain the injection.
[0055] Example 2
[0056] This embodiment provides an injection containing sodium hyaluronate, comprising the following components in parts by weight: 1.4 parts of cross-linked sodium hyaluronate, 0.65 parts of carnosine, 0.4 parts of amino acids, 0.6 parts of vitamin B3, 0.8 parts of sodium chloride, 0.008 parts of sodium dihydrogen phosphate, 0.01 parts of sodium dihydrogen phosphate, 0.3 parts of animal collagen, 0.15 parts of cell extract and 98.7 parts of water for injection;
[0057] The amino acids include the following components in parts by weight: 1 part of arginine, 8 parts of serine, 3 parts of leucine, 4 parts of alanine and 8 parts of cysteine.
[0058] The preparation method of the cross-linked sodium hyaluronate comprises the following steps:
[0059] (1) Mixing medium-molecular sodium hyaluronate, macromolecular sodium hyaluronate and ultra-large-molecular sodium hyaluronate to obtain mixed sodium hyaluronate; the weight ratio of medium-molecular sodium hyaluronate, macromolecular sodium hyaluronate and ultra-large-molecular sodium hyaluronate is 1.2:1:0.4. The molecular weight of the medium-molecular sodium hyaluronate is about 450KDa; the molecular weight of the macromolecular sodium hyaluronate is about 1320KDa; and the molecular weight of the ultra-large-molecular sodium hyaluronate is about 1750KDa;
[0060] (2) adding 0.5 mol / L sodium hydroxide aqueous solution to 100 parts by weight of mixed sodium hyaluronate to adjust the pH to 11, and then adding 1 part by weight of a cross-linking agent, stirring and reacting at 30° C. for 4-6 hours; the cross-linking agent is a mixture of 1,4-butanediol diglycidyl ether, genipin, and ethylene glycol diglycidyl ether in a weight ratio of 1:1.2:0.5;
[0061] (3) adding 320 parts by weight of ethanol to precipitate, and then adding 2% by weight of a hydrogen chloride aqueous solution to adjust the pH value to neutral to obtain a precipitate; washing the precipitate with ethanol 5 times, and filtering to obtain a wet powder;
[0062] (4) The wet powder is vacuum dried at 30° C. to obtain cross-linked sodium hyaluronate.
[0063] The preparation method of the animal collagen comprises the following steps:
[0064] (1) crushing cod bones and passing through a 200-mesh sieve to obtain cod bone powder;
[0065] (2) mixing cod bone powder and a 9% sodium chloride aqueous solution in a weight ratio of 1:6, soaking for 12 hours, filtering and retaining the precipitate, washing with deionized water for 5 times, drying, adding ethyl acetate 5 times the weight of the cod bone powder and soaking again for 10 hours, filtering, drying, and then crushing to 50-100 mesh to obtain a pretreated cod bone powder;
[0066] (3) Pretreated cod bone powder and water at 37° C. in a weight ratio of 1:35 are mixed to obtain a mixed liquid, and a composite enzyme is added, wherein the composite enzyme includes pepsin, papain and trypsin. The amount of pepsin used in the mixed liquid is 70 U / mL; the amount of papain used in the mixed liquid is 110 U / mL; the amount of trypsin used in the mixed liquid is 90 U / mL; after enzymatic hydrolysis for 5 hours, the mixture is filtered, and the filtrate is added with 2.6 mol / L sodium chloride aqueous solution for salting out for 1 hour, centrifuged, and the supernatant is collected, and the supernatant is dialyzed to retain substances with a molecular weight between 30,000 Da and 50,000 Da, and freeze-dried to obtain animal collagen.
[0067] The preparation method of the cell extract comprises the following steps:
[0068] (1) Wash and drain the amniotic membrane, umbilical cord and placenta of a healthy full-term pregnant woman who is free of hepatitis B, hepatitis C, HIV and syphilis virus;
[0069] (2) weighing amniotic membrane, umbilical cord and placenta in a weight ratio of 1:1.2:0.5 to obtain a mixed raw material, mixing the mixed raw material in a weight ratio of 4.5:1 with 0.8% by mass of physiological saline, and mashing the mixed raw material to obtain a placenta tissue slurry;
[0070] (3) Mixing the placental tissue slurry in a weight ratio of 1:4.5 with 0.8% by weight of normal saline, and dialyzing the mixture for 3 times, each time for 30 hours, to obtain a dialysate;
[0071] (4) The dialysate was clarified to obtain a supernatant, which was first filtered through a filter element with a pore size of 0.75 μm, and then ultrafiltered using a membrane with a molecular weight of 6000 Daltons; after ultrafiltration, the virus was inactivated at 60°C for 10 hours to obtain a cell extract.
[0072] The preparation method of the injection containing sodium hyaluronate is as follows: mixing the components in the formula, stirring evenly, and starting a vacuum bubble removal process to obtain the injection.
[0073] Comparative Example 1
[0074] The difference between this comparative example and Example 1 is that the weight ratio of medium-molecular sodium hyaluronate, large-molecular sodium hyaluronate and ultra-large-molecular sodium hyaluronate is 1:1:1.
[0075] Comparative Example 2
[0076] The difference between this comparative example and Example 1 is that the molecular weight of the medium-molecular sodium hyaluronate is 100K-200KDa; the molecular weight of the large-molecular sodium hyaluronate is 1600K-1700KDa; and the molecular weight of the ultra-large-molecular sodium hyaluronate is 1900K-2000KDa.
[0077] Comparative Example 3
[0078] The difference between this comparative example and Example 1 is that the cross-linking agent is a mixture of 1,4-butanediol diglycidyl ether, genipin, and ethylene glycol diglycidyl ether in a weight ratio of 1:1:1.
[0079] Comparative Example 4
[0080] The difference between this comparative example and Example 1 is that the cross-linking agent is a mixture of 1,2,7,8-diepoxyoctane, 1,3-diepoxybutane and sodium trimetaphosphate in a weight ratio of 1:1.3:0.7.
[0081] Comparative Example 5
[0082] The difference between this comparative example and Example 1 is that the complex enzyme is pepsin.
[0083] Comparative Example 6
[0084] The difference between this comparative example and Example 1 is that the compound enzyme includes pepsin, papain and trypsin. The amount of pepsin used in the mixed liquid is 105 U / mL; the amount of papain used in the mixed liquid is 85 U / mL; and the amount of trypsin used in the mixed liquid is 65 U / mL.
[0085] Comparative Example 7
[0086] The difference between this comparative example and Example 1 is: an injection solution containing sodium hyaluronate, comprising the following components in parts by weight: 1 part of cross-linked sodium hyaluronate, 0.7 part of carnosine, 0.5 part of amino acid, 0.4 part of vitamin B3, 0.9 part of sodium chloride, 0.007 part of sodium dihydrogen phosphate, 0.015 part of sodium hydrogen phosphate, 0.8 part of animal collagen, 0.19 part of cell extract and 98 parts of water for injection.
[0087] Comparative Example 8
[0088] The difference between this comparative example and Example 1 is that the amino acids include the following components in parts by weight: 7 parts of arginine, 5 parts of serine, 5 parts of leucine, 5 parts of alanine and 5 parts of cysteine.
[0089] Performance Testing
[0090] Test samples: injection solutions of Examples 1-2 and Comparative Examples 1-8.
[0091] 1. Irritation test - Animal intradermal reaction test
[0092] This test is based on the method recommended in the national standard GB / T16886.10-2017 "Biological Evaluation of Medical Devices Part 10: Irritation and Skin Sensitization Test" to evaluate the intradermal reaction of the test samples.
[0093] Three rabbits were selected for each test group. Each test sample and control (water for injection) were injected into the animal's back skin. The conditions of each injection site were observed immediately, 24h, 48h and 72h after injection, and the recorded results of 24h, 48h and 72h were used as the final score for calculation. After the 72h score, all the erythema and edema scores of each animal's test sample and control at 24h, 48h and 72h were added, and then divided by 15 [3 (scoring time point) x 5 (test sample or control injection point)] to calculate the score of each animal's test sample and control. The total average score of each test sample and corresponding control was obtained by adding the scores of the three animals and dividing by 3.
[0094] The final score of the test sample can be obtained by subtracting the control score from the test sample score. If the final score of the test sample is not greater than 1.0, it meets the test requirements. During any observation period, if the average reaction of the test sample is suspected to be greater than the control reaction, 3 more rabbits should be taken for retesting. If the final score of the test sample is not greater than 1.0, it meets the test requirements.
[0095] Under the test conditions, the final scores of all test samples were less than 1.0, which meets the requirements of the intradermal reaction test in the GB / T16886.10-2017 "Biological Evaluation of Medical Devices Part 10: Irritation and Skin Sensitization Test" standard.
[0096] 2. Skin sensitization test (maximum dose method, direct application)
[0097] This test is used to evaluate the possible skin sensitization caused by the chemical substances released by the sample. The test is based on the standard GB / T16886.10-2017 "Biological Evaluation of Medical Devices Part 10: Irritation and Skin Sensitization Test".
[0098] Test samples: water for injection and 0.01g / mL 2,4-dinitrochlorobenzene anhydrous ethanol solution were injected into the skin of each test group according to the standard method. 7 days after intradermal injection, a local application test was performed. 14 days after local application, a provocation test was performed on the skin on the side of the spine of the test animal that was not treated with the test. The provocation patch was bandaged for 24 hours, and the erythema and edema of the skin of each group of animals were observed 24 hours and 48 hours after the patch was removed.
[0099] The test results show that the skin of the animals in the test group of the present invention had no erythema and edema, and the grade of erythema and edema of the animal skin was <1, and the skin of the animals in the negative control (water for injection) group had no erythema and edema, and the grade of erythema and edema of the animal skin was <1. Obvious erythema and edema were observed on the skin of the animals in the positive control group (0.01 g / mL 2,4-dinitrochlorobenzene anhydrous ethanol solution), and eschar and hemorrhage were observed on the skin of some animals, and the incidence of skin sensitization reaction of the animals in this group was 100%.
[0100] Under the test conditions, none of the test samples caused skin sensitization.
[0101] 3. Study on the degradation experiment of cross-linked sodium hyaluronate.
[0102] Test sample: cross-linked sodium hyaluronate prepared in Example 1-4; physiological saline was used as a blank control, and the subcutaneous hyaluronic acid content of mice was measured at the same time.
[0103] Experimental animals: 60 healthy mice.
[0104] Experimental method: 60 mice were randomly divided into 5 groups, 12 mice in each group. Each group of mice was further divided into a test group 2 weeks after injection, a test group 3 weeks after injection, and a test group 4 weeks after injection. After subcutaneous injection, each group of mice was killed at the experimental test point, and 1cm*1cm skin tissue from the injection site was taken, digested with pancreatic enzyme solution, and centrifuged to obtain the supernatant. Referring to the sodium hyaluronate detection method in "YYT0308-2015 Medical Sodium Hyaluronate Gel", the content of cross-linked sodium hyaluronate in the supernatant was detected, and the hyaluronic acid content of the mouse subcutaneous itself was deducted to calculate the residual content of sodium hyaluronate in the mouse subcutaneous.
[0105] Calculation method: The residual sodium hyaluronate content in mouse subcutaneous tissue = (the sodium hyaluronate content in the supernatant - the hyaluronic acid content in mouse subcutaneous tissue) / the amount of cross-linked sodium hyaluronate in the injection solution × 100%.
[0106] The results are shown in Table 1.
[0107] Table 1 Results of residual sodium hyaluronate content (%)
[0108] 2 weeks 3 weeks 4 weeks Example 1 55.1 28.5 17.5 Example 2 54.3 28.1 17.0 Comparative Example 1 51.4 22.4 11.5 Comparative Example 2 52.2 21.1 12.8 Comparative Example 3 50.9 23.5 10.7 Comparative Example 4 50.3 23.0 10.3
[0109] 4. Test product: injection solution prepared in Examples 1-2 and Comparative Examples 1-8 (2.0 mL / vial).
[0110] Subjects: 100 healthy volunteers aged 30-50 years old were selected, regardless of gender, and randomly divided into groups of 10. Among them, the exclusion criteria include: patients with major systemic diseases being treated, pregnant and lactating women, patients with skin lesions and surgical history at the test site, and patients with a history of dermatological treatment within the past month.
[0111] Use the injection solution as required, for a total of three injections, 2 injections each time, including the first injection, injection 28 days after the first injection (second injection), and injection 28 days after the second injection (final injection). Before the first injection and 28 days after the last injection, use a skin elasticity tester to test elasticity and moisture. The measurement sites include the left zygomatic bone, right zygomatic bone, center of the forehead, and mandible. Each site is measured 3 times, and the mean measurement value of the left zygomatic bone, the mean measurement value of the right zygomatic bone, the mean measurement value of the center of the forehead, and the mean measurement value of the mandible are calculated respectively, and then the average value of all measurement sites is calculated. The relative humidity in the test room is maintained at 55% ± 5%, and the room temperature is 25℃ ± 1℃. Before the test, the subject enters the test room and rests for 30 minutes. Testing instrument: German CK Skin Elasticity Tester MPA580.
[0112] Mean elasticity = (mean value of left zygomatic bone elasticity measurement + mean value of right zygomatic bone elasticity measurement + mean value of forehead midline elasticity measurement + mean value of mandibular elasticity measurement) / 4.
[0113] Table 2 Effect of injection on skin elasticity
[0114]
[0115] From the above performance test results, it can be seen that the degradation rate of the cross-linked sodium hyaluronate in the injection of Examples 1-2 is slow, and the injection has a good effect on improving skin elasticity, especially the comprehensive performance of Example 1 is the most outstanding, which is mainly due to the synergistic effect of the components of the injection.
[0116] However, the comparative examples did not adopt the necessary technical solutions, resulting in that they were significantly worse than the embodiments in the corresponding performance tests. In comparative example 1, the raw materials for preparing cross-linked sodium hyaluronate were changed, and it can be seen that the effect of delaying degradation decreased. In comparative examples 5-6, the composite enzyme solution with a specific ratio was not used. From the results, it can be seen that the component composition in the animal collagen was affected, further resulting in a decrease in the elasticity effect of improving the skin. In comparative example 7, the ratios of cross-linked sodium hyaluronate and animal collagen were different, and the elasticity effect of improving the skin decreased, indicating that the two components can play a synergistic role. Comparative example 8 shows that the present invention can increase the skin collagen content through the compounded amino acids, so that the skin presents a younger change, and at the same time has a better inhibitory effect on sodium hyaluronate enzyme. The above experimental results further prove the importance of the technical solution defined in the present invention for its technical effect.
[0117] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An injection containing sodium hyaluronate, characterized in that: The invention comprises the following components in parts by weight: 1.4-1.8 parts of cross-linked sodium hyaluronate, 0.4-0.9 parts of carnosine, 0.4-0.6 parts of amino acids, 0.2-0.6 parts of vitamin B3, 0.8-1.2 parts of sodium chloride, 0.002-0.008 parts of sodium dihydrogen phosphate, 0.01-0.02 parts of sodium dihydrogen phosphate, 0.1-0.3 parts of animal collagen and 95-100 parts of water for injection; The preparation method of the cross-linked sodium hyaluronate comprises the following steps: (1) mixing medium molecular sodium hyaluronate, large molecular sodium hyaluronate and ultra-large molecular sodium hyaluronate to obtain mixed sodium hyaluronate; (2) adding a 0.5-0.9 mol / L sodium hydroxide aqueous solution to 100 parts by weight of the mixed sodium hyaluronate to adjust the pH to 10-11, and then adding 1-3 parts by weight of a cross-linking agent, stirring and reacting at 20-30° C. for 4-6 hours; (3) continuing to add 320-350 parts by weight of ethanol to precipitate, and then adding 2-5% by weight of a hydrogen chloride aqueous solution to adjust the pH value to neutral to obtain a precipitate; washing the precipitate with ethanol 3-5 times, and filtering to obtain a wet powder; (4) The wet powder is vacuum dried at 30-40° C. to obtain cross-linked sodium hyaluronate.
2. The injection containing sodium hyaluronate according to claim 1, characterized in that: Also included is 0.15-0.24 parts of a cell extract comprising an extract of amniotic membrane, umbilical cord and / or placental cells.
3. The injection containing sodium hyaluronate according to claim 1, characterized in that: The weight ratio of medium-molecular sodium hyaluronate, large-molecular sodium hyaluronate and super-large-molecular sodium hyaluronate is (1.2-1.5):1:(0.4-0.7).
4. The injection containing sodium hyaluronate according to claim 2, characterized in that: The molecular weight of the medium-molecular sodium hyaluronate is 400K-500KDa; the molecular weight of the large-molecular sodium hyaluronate is 1300K-1400KDa; and the molecular weight of the ultra-large-molecular sodium hyaluronate is 1700K-1800KDa.
5. The injection containing sodium hyaluronate according to claim 1, characterized in that: The cross-linking agent is a mixture of 1,4-butanediol diglycidyl ether, genipin and ethylene glycol diglycidyl ether in a weight ratio of 1: (1.2-1.4): (0.5-0.8).
6. The injection containing sodium hyaluronate according to claim 1, characterized in that: The amino acids include the following components in parts by weight: 1-3 parts of arginine, 5-8 parts of serine, 3-6 parts of leucine, 2-4 parts of alanine and 5-8 parts of cysteine.
7. The injection containing sodium hyaluronate according to claim 1, characterized in that: The preparation method of the animal collagen comprises the following steps: (1) crushing cod bones and passing through a 100-200 mesh sieve to obtain cod bone powder; (2) mixing cod bone powder and a sodium chloride aqueous solution with a weight ratio of 1: (6-10) and soaking for 12-15 hours, filtering and retaining the precipitate, washing with deionized water for 3-5 times, drying, adding ethyl acetate 5-7 times the weight of the cod bone powder and soaking again for 8-10 hours, filtering, drying, and finally crushing to 50-100 mesh to obtain pretreated cod bone powder; (3) Pretreated cod bone powder and water at 35-37° C. in a weight ratio of 1:(35-40) are mixed to obtain a mixed liquid, a composite enzyme is added, and after enzymatic hydrolysis for 5-7 hours, the mixed liquid is filtered, and the filtrate is added with a 2.4-2.6 mol / L sodium chloride aqueous solution for salting out for 1-2 hours, centrifuged, and the supernatant is collected and dialyzed to retain substances with a molecular weight between 30,000 Da and 50,000 Da, which are freeze-dried to obtain animal collagen.
8. The injection containing sodium hyaluronate according to claim 7, characterized in that: The complex enzyme comprises pepsin, papain and trypsin; the usage amount of pepsin in the mixed liquid is 60-70 U / mL; the usage amount of papain in the mixed liquid is 110-120 U / mL; the usage amount of trypsin in the mixed liquid is 80-90 U / mL.
9. A method for preparing an injection containing sodium hyaluronate according to any one of claims 1 to 8, characterized in that: The preparation method comprises the following steps: mixing the components in the formula amount, stirring evenly, and starting a vacuum bubble removal process to obtain an injection solution.
10. Use of the injection containing sodium hyaluronate according to any one of claims 1 to 8.
Citation Information
Patent Citations
Method for extracting collagen from fish processing waste including skin, bones and scale
CN102154421A
Injectable crosslinked hyaluronic acid gel and preparation method thereof
CN103834053A
Enzymolysis-resistant crosslinked sodium hyaluronate gel, and preparation method and preparations thereof
CN108250462A
Cross-linked sodium hyaluronate composite solution preparation as well as preparation method and application thereof
CN111467568A
